SEC Form 4 · accession 0000899243-17-015022
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanofi
10% Owner
Period of report
May 31, 2017
Accepted (ET)
Jun 1, 2017 · 7:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 31, 2017 | P | 297,501 | $71.87 | A | 10,554,134 | I | Via wholly-owned subsidiary, Genzyme Corp. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Purchase of shares in accordance with the terms of the investor agreement between Alnylam and Genzyme (a Sanofi company) dated February 27, 2014.